Yep! These yo yo moves in the stock price are getting quite annoying, but becoming great opportunities to accumulate before the gold rush starts.
I'd really like to know what would the consensus be if the company did announce they would market this otc.
Would the pps look at that positively and increase or nosedive??
Would demand for the product be higher due to lower cost , thereby offsetting the decline in revenue??
Would you be a buyer of stock if that occurred??
The Food and Drug Administration says it’s planning to overhaul the slow and clumsy system for regulating over-the-counter drugs from aspirin to eye drops and is asking for public input.
Both drugmakers and consumer advocates have been pressing for the changes. Companies that make the products want more flexibility, while consumer watchdogs say FDA needs to move more quickly to restrict dangerous products.
Image: Cold and flu products FRED PROUSER / REUTERS FILE
Cold and flu products
FDA says it’s seeking public input and announced a two-day meeting at the end of March.
Right now, over the counter, or OTC, products are regulated mostly using what’s called a monograph — a listing of the ingredients in the product and what they are allowed to be used for. “OTC products that meet a monograph’s requirements may be marketed without FDA review,” the agency says on its website.
It’s not anywhere near as strict as the process FDA uses to approve prescription drugs, which must be tested and shown to be effective and safe. Sometimes prescription products get moved to OTC status, but usually new OTC drugs can go on the market without any testing so long as they contain recognized ingredients.
The system has been around since 1972, but it’s time-consuming and many common pain relievers and cough medicines are still technically under review, even though they are freely available on the shelves.
It worries some regulators at FDA, who would like to lower the available doses of drugs such as acetaminophen, which can cause fatal liver damage. It took FDA decades to finally take a stand against triclosan, an antibacterial ingredient in hand and dish soaps. Last month FDA finally proposed forcing manufacturers to prove that adding the ingredient was beneficial and not harmful.
“The Agency is interested in exploring ways to re-engineer the process of regulating OTC drugs that are currently regulated under the OTC Monograph Process to, among other things, create a process that is more efficient and more responsive to newly emerging information and evolving science, and to allow for more rapid product innovation where appropriate,” FDA said in announcing the meeting, to be held March 25 and 26 outside Washington D.C.
That's the thing I'm watching for.
Volume uptick followed by share price movement up or down.
But even with that you just never know for sure.
It's really getting boring watching one computer selling and another buying all day.
Just don't know how you keep cool when you're holding so many shares of this Kitty.
I couldn't do it!
Yes, it's pretty funny how bio's clam up when there is a failure of sorts.
VICL mgmt did the same, until mgmt took a stand and made big share purchases at 1.41.
Of course that tends to stabilize the share price after the sudden pop to 1.79 occurred.
Even SA writers have clammed up since the bad news hit on vtus.
Guess that means everyone is waiting which may cause further weakness in the shares over time if nothing is said. But I'm sure mgmt is well aware of this.
Apples and oranges run and owned by the same business man calling the shots, with the same high dividend, high debt strategy.
You can pat Mr. JF on the back while things are holding up just like others did on the FRO message board.
If you read many of my posts on that board several years ago, you would know that I was right about the direction and JF's moves to leave FRO a shell company that only leases and pays no dividend.
I have not called the death of SDRL and only warned about buying weeks ago as the stock would inflate for a day or two in order to suck you in and then fall down further.
That's why I was urging caution leading up to earnings.
I didn't tell you not to buy, nor to sell.
I do take issue with you on whether there will be a supply glut at some point, or whether rates could fall and I think there are quite a few others adding to their fleets.
Your comments are the same as I read about FRO when it was trading in 50's and 60's.and caught many by surprise.
You also seem to be ignoring the long term effects of fracking to the supply glut many are predicting.
And don't forget the risk associated in a BP type disaster on SDRL which may be remotely possible but could cause a shutdown of drilling.
And last but not least any part of the earnings report that raises concern by the big holders of SDRL.
That's the reason I am waiting for direction on earnings to buy more or sell.
We shall see if caution is warranted.
"The new company, called SeaMex, will be owned 50 percent by Seadrill and 50 percent by the Fintech fund."
I never said I lost on FRO, and as stated above Fintech owns half of SeaMex.
Do you really think Fintech put up 488 million just to own a title.
Ask yourself what would secure your loan if you invested 488 million in a joint venture with sdrl.
If I own half the company I want half ownership in those rigs.
We realize that you have strong opinions and don't mind hearing them, but could you combine them into one or two posts.
Your multiple post's drown out all other comments on the board.
I really don't want to put you on ignore.